Clozapine improves dyskinesias in Parkinson disease A double-blind, placebo-controlled study

Neurology

Volumn 62, Issue 3, 2004, Pages 381-388

  Durif, F ^a   Debilly, B ^a   Galitzky, M ^a   Morand, D ^a   Viallet, F ^a   Borg, M ^a   Thobois, S ^a   Broussolle, E ^a   Rascol, O ^a  

^a SERVICE DE RHUMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; LEVODOPA;

ADULT; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; ASTHENIA; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; DYSPNEA; DYSTONIA; EOSINOPHILIA; FALLING; HALLUCINATION; HUMAN; HYPEREOSINOPHILIA; HYPERSALIVATION; HYPOTENSION; INSOMNIA; MOTOR PERFORMANCE; MULTICENTER STUDY; NAUSEA; NIGHTMARE; ON OFF PHENOMENON; OUTCOMES RESEARCH; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCORING SYSTEM; SELF EVALUATION; SIDE EFFECT; SOMNOLENCE; STOMACH PAIN; URINARY TRACT INFECTION; VERTIGO; WEIGHT GAIN;

EID: 1042299831     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000110317.52453.6C     Document Type: Article

References (42)

1. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease-clinical aspects. In: Marsden CD, Fahn S, eds. Movement disorders. London: Butterworth, 1982:96-122.
2. Nutt JG. Dyskinesia induced by levodopa and dopamine agonists in patients with Parkinson's disease. In: Lang AE, Weiner WJ, eds. Drug-induced movement disorders. Mt. Kisco, NY: Futura, 1992:281-314.
3. Muenter MD, Sharpless NS, Tya GM, Darley FL. Patterns of dystonia ("I-D-I" and "D-I-D") in response to L-dopa therapy for Parkinson's disease. Mayo Clin Proc 1977;52:163-174.
4. Lhermitte F, Agid Y, Signoret JL, Studler JM. Les dyskinesies de "début et fin de dose" provoquées par la L-DOPA. Rev Neurol 1977;133: 297-308.
5. Lhermitte F, Agid Y, Signoret JL. Onset and end-of-dose levodopa-induced dyskinesia, possible treatment by increasing the daily doses of levodopa. Arch Neurol 1978;35:261-263.
6. Del Dotto P, Pavese N, Gambaccini G, et al. Intravenous amantadine improves levodopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord 2001;16:515-520.
7. Parkin SG, Gregory RP, Scott R, et al. Unilateral and bilateral pallidotomy for idiopathic Parkinson's disease: a case series of 115 patients. Mov Disord 2002;17:682-692.
8. Krack P, Pollak P, Limousin P, et al. Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease. Brain 1998; 121:451-457.
9. Limousin-Dowsey P, Pollak P, Van Blercom N, et al. Thalamic, subthalamic nucleus and internal pallidum stimulation in Parkinson's disease. J Neurol 1999;246:42-45.
10. Durif F, Lemaire JJ, Debilly B, Dordain G. Acute and chronic effects of anteromedial globus pallidus stimulation in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67:315-322.
11. Criswell HE, Mueller RA, Breese GA. Clozapine, antagonism of D-1 and D-2 dopamine receptor-mediated behaviors. Eur J Pharmacol 1989;159: 141-147.
12. Murray AM, Waddington JL. The interaction of clozapine with dopamine D1 versus dopamine D2 receptor-mediated function: behavioral indices. Eur J Pharmacol 1990;186:79-86.
13. Van Tol HH, Bunzow JR, Guan HC, et al. Cloning of the gene for a human dopamine D4 receptor with affinity for the antipsychotic clozapine. Nature 1991;350:610-614.
14. Seeman P. Dopamine receptor sequences: therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 1992;7:261-284.
15. Baldessarini RJ, Frankenburg FR. Clozapine, a novel antipsychotic agent. N Engl J Med 1991;324:746-754.
16. Meltzer HY. An overview of the mechanism of action of clozapine. J Clin Psychiatry 1994;55(suppl B):47-52.
17. Povlsen UJ, Noring U, Fog R, Gerlach J. Tolerability and therapeutic effect of clozapine. Acta Psychiatr Scand 1985;71:176-185.
18. Kane JM, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796.
19. Kane JM, Lieberman J, Pollak S, Safferman A. Clozapine and tardive dyskinesia: prospective data. Schizophr Res 1991;4:364-365.
20. The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet 1999;353:2041-2042.
21. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999;340: 757-763.
22. Gomez Arevalo GJ, Gershanik OS. Modulatory effect of clozapine on levodopa response in Parkinson's disease: a preliminary study. Mov Disord 1993;8:349-354.
23. Bennett JP, Landow ER, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 1993;43:1551-1555.
24. Bennett JP, Landow ER, Dietrich S, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long term dyskinesia reduction. Mov Disord 1994;9:409-414.
25. Durif F, Vidailhet M, Assal F, Roche C, Bonnet AM, Agid Y. Low dose clozapine improves dyskinesias in Parkinson's disease. Neurology 1997; 48:658-661.
26. Hughes AD, Daniel SE, Kilford L, Lees AJ. The accuracy of clinical diagnosis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1992;55:181-185.
27. Fahn S, Elston RLL, and members of the UPDRS Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent developments in Parkinson's disease, vol 2. New York: Macmillan Healthcare, 1987:153-163.
28. Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesia in Parkinson's disease. Phenomenology and pathophysiology. Mov Disord 1994;9:2-12.
29. Durif F, Vidailhet M, Debilly B, Bonnet AM, Agid Y. Worsening of levodopa-induced dyskinesias by motor and mental tasks. Mov Disord 1999;14:242-245.
30. Goetz CG, Stebbins GT, Shale HM, et al. Evaluation of intra- and interrater reliability in dyskinesia rating scale for Parkinson's disease. Mov Disord 1993;8:416.
31. Chatterton R. Eosinophilia after commencement of clozapine treatment. Aust NZ J Psychiatry 1997;31:874-876.
32. Mouradian MM, Heuser IJE, Baronti F, et al. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 1989;25:523-526.
33. Bedard PJ, Di Paolo T, Salardeau P, Boucher R. Chronic treatment with L-dopa but not bromocriptine, induces dyskinesia in MPTP-parkinsonian monkeys: correlation with (3 H) spiperone binding. Brain Res 1986;379:294-299.
34. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;18:1484-1491.
35. Farde L, Wiesel FA, Nordstrom AL, Sedvall G. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology (Berl) 1989;99(suppl):S28-S31.
36. Nordstrom AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995;152:1444-1449.
37. Marazziti D, Marracci S, Palego L, et al. Localization and gene expression of serotonin 1A (5HT1A) receptors in human brain postmortem. Brain Res 1994;26:55-93.
38. Newman-Tancredi A, Gavaudan S, Conte C, et al. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTP-gammaS binding study Eur J Pharmacol 1998;21:245-256.
39. Bibbiani F, Oh JD, Chase TN. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001;57:1829-1834.
40. Rodriguez JJ, Garcia DR, Pickel VM. Subcellular distribution of 5-hydroxytryptamine2A and N-methyl-D-aspartate receptors within single neurons in rat motor and limbic striatum. J Comp Neurol 1999;18: 219-312.
41. Gomez-Mancilla B, Bedard PJ. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 1993;16:418-427.
42. Henderson J, Yiannikas C, Graham JS. Effect of ritanserin, a highly selective 5-HT2 receptor antagonist, on Parkinson's disease. Clin Exp Neurol 1992;29:277-282.